Open-label Study of Bevacizumab Maintenance Therapy (AVASTIN) With or Without Pemetrexed After First-line Chemotherapy With Bevacizumab-cisplatin-pemetrexed in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC).

Trial Profile

Open-label Study of Bevacizumab Maintenance Therapy (AVASTIN) With or Without Pemetrexed After First-line Chemotherapy With Bevacizumab-cisplatin-pemetrexed in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AVAPERL; AVAPERL-1
  • Sponsors Roche
  • Most Recent Events

    • 30 Jan 2014 Last checked against German Clinical Trials Register, DRKS00003765.
    • 08 Jul 2013 Results published in the Journal of Clinical Oncology.
    • 04 Jun 2013 Updated overall survival analysis presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top